RecruitingPhase 1NCT06597721

ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

First-in-Human, Phase 1 Study of ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors

Sponsor

Adcendo ApS

Enrollment

210 participants

Start Date

Nov 25, 2024

Study Type

INTERVENTIONAL

Conditions

Advanced Solid Tumor

Summary

Adcendo ApS is conducting a phase 1 study of an investigational drug called ADCE-T02 (previously known as AMT-754), a tissue factor targeted antibody-drug conjugate which may be used in the future as a possible treatment for advanced solid tumors. The main purpose of the study is to determine the Maximum Tolerated Dose (MTD), the recommended dose and the safety and tolerability of ADCE-T02 when given as a single therapy over a range of different dose levels.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called ADCE-T02 for people with advanced solid tumor. The study is currently recruiting participants at 11 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGADCE-T02

Administered intravenously

Locations(12)

Highlands Oncology Group

Rogers, Arkansas, United States

Yale University Cancer Center

New Haven, Connecticut, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

MD Anderson Cancer Center

Houston, Texas, United States

START San Antonio

San Antonio, Texas, United States

Macquarie University Hospital

Macquarie Park, New South Wales, Australia

Scientia Clinical Research

Randwick, New South Wales, Australia

Southern Oncology Clinical Research Unit

Bedford Park, South Australia, Australia

Peninsula and South Eastern Haematology and Oncology Group (PSEHOG)

Frankston, Victoria, Australia

Cabrini Hospital

Malvern, Victoria, Australia

Peter MacCallum Cancer Centre

Melbourne, Victoria, Australia

Linear Clinical Research

Nedlands, Western Australia, Australia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06597721

Related Trials

A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours

NCT0683300813 locations

A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors

NCT076694151 location

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies

NCT0721383011 locations

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

NCT0526762618 locations

A Study of IDP-001 in Advanced or Metastatic Solid Tumors

NCT076028424 locations